Zus Health Achieves HITRUST r2 Certification, Demonstrating Commitment to Cybersecurity and Information Protection Yahoo! Finance Canada
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
